FDA Launches PreCheck Pilot to Fast-Track Drug Manufacturing

The PreCheck initiative marks a strategic shift for the FDA, moving from a reactive inspection model to a proactive oversight process. Alongside Lilly and Regeneron, the inaugural cohort includes Amneal, Cellares, Fujifilm Biotechnologies, Kriya Therapeutics, and Kyowa Kirin. The program targets facilities capable of producing essential drugs or filling market supply gaps, with a heavy emphasis on complex biologics and genetic therapies that require specialized manufacturing infrastructure.

According to FDA spokesperson Benjamin Nichols, the program allows for early identification and resolution of compliance issues before a facility is fully operational. This effort aligns with broader federal goals to bolster domestic pharmaceutical production capacity. To qualify, companies must demonstrate that their new facilities address unmet medical needs or resolve existing supply shortages, ensuring that the expedited review process directly benefits patient access to complex treatments.